Mnemo Therapeutics Announces Publication in Cancer Discovery on Ablation of SUV39H1 for Long-Term Protection Against Solid Tumors

Study shows that ablating the histone methyltransferase SUV39H1 enhances T cell memory/persistence, reduces T cell exhaustion, and provides protection against tumor relapses in mouse models PARIS, Nov. 7, 2023 /PRNewswire/ — Mnemo Therapeutics, a biotechnology company developing…